RecruitingPhase 2NCT07335796

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

A Phase 2 Study of Androgen Deprivation Therapy and BMS986365 in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

30 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called BMS986365 combined with degarelix (a hormone-blocking injection) in men with high-risk localized prostate cancer who are planning to have surgery to remove the prostate. The goal is to see if adding this drug before surgery can shrink or eliminate the cancer more effectively. **You may be eligible if...** - You are male and 18 or older - You have been diagnosed with high-risk localized prostate cancer (e.g., PSA ≥ 20, Gleason score ≥ 8, or tumor extending outside the prostate capsule) - You are a candidate for prostate removal surgery - Your blood counts and organ function meet the required thresholds **You may NOT be eligible if...** - Your cancer has spread to lymph nodes or distant organs - You have significant heart, liver, or kidney problems - You are unable to tolerate hormone therapy or surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986165

BMS986365 (CC-94676) is an androgen receptor (AR) ligand-directed degrader that was designed to target the AR for degradation in castration-resistant prostate cancer (CRPC)

DRUGDegarelix

Degarelix is a GnRH antagonist that blocks the action of GnRH on the pituitary and effectively suppresses testosterone production